nifedipine has been researched along with Disease Exacerbation in 34 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine." | 9.27 | Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018) |
| "To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 9.15 | Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011) |
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 9.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| "Our data show that both lisinopril and nifedipine are effective in delaying the occurrence of macroalbuminuria in normotensive IDDM patients with MA." | 9.08 | Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. ( Carta, Q; Crepaldi, G; Deferrari, G; Mangili, R; Navalesi, R; Nosadini, R; Santeusanio, F; Spalluto, A; Vanasia, A; Villa, GM, 1998) |
| " We show that nifedipine (NIFE), a calcium channel blocker, inhibits calcium influx to impair nuclear factor of activated T cell 2 (NFAT2) dephosphorylation, activation, and nuclear translocation, thus preventing transcriptional activation of downstream signaling molecules to suppress colorectal cancer (CRC) proliferation and metastasis." | 7.96 | Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation. ( Chen, Z; Ding, Y; Li, K; Lian, W; Liao, Q; Lin, C; Lin, W; Tang, L; Wang, H; Wu, L; Xu, L; Zhao, L; Zhou, R, 2020) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| " In both age groups, chronic nifedipine administration reduced neurogenic contractions of isolated superior mesenteric artery, but did not significantly affect the dose-response curve to exogenous noradrenaline in 8-week-old rats." | 5.35 | Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. ( Török, J; Zemančíková, A, 2009) |
| "Treatment with nifedipine resulted in a significant inhibition of the progression of AAA such as aneurismal dilation at 14 and 28 days compared to the control (week 2: control, 2." | 5.35 | Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. ( Izawa, K; Kunugiza, Y; Morishita, R; Ogihara, T; Osako, MK; Tomita, N; Yamasaki, K, 2008) |
| "This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine." | 5.27 | Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018) |
| "To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)." | 5.15 | Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011) |
| "To assess the efficacy of an angiotensin converting enzyme (ACE) inhibitor (perindopril), a dihydropyridine calcium channel blocker (sustained release nifedipine) and placebo in preventing the progression of albuminuria and decline in glomerular filtration rate (GFR) in patients with Type 2 diabetes and microalbuminaria." | 5.11 | Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. ( Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; O'Brien, RC; Raffaele, J; Tsalamandris, C, 2004) |
| " The study was designed as a side arm of INSIGHT (International Nifedipine Study: Intervention as Goal for Hypertension Therapy), aimed to show the efficacy of nifedipine once daily versus co-amilozide (hydrochlorothiazide 25 mg, amiloride 2." | 5.09 | Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. ( Motro, M; Shemesh, J, 2001) |
| "This study, ancillary to the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), involved nifedipine 30 mg or co-amilozide (hydrochlorothiazide 25 mg and amiloride 2." | 5.09 | Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. ( Gariépy, J; Levenson, J; Moyse, D; Simon, A, 2001) |
| "Our data show that both lisinopril and nifedipine are effective in delaying the occurrence of macroalbuminuria in normotensive IDDM patients with MA." | 5.08 | Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. ( Carta, Q; Crepaldi, G; Deferrari, G; Mangili, R; Navalesi, R; Nosadini, R; Santeusanio, F; Spalluto, A; Vanasia, A; Villa, GM, 1998) |
| " We show that nifedipine (NIFE), a calcium channel blocker, inhibits calcium influx to impair nuclear factor of activated T cell 2 (NFAT2) dephosphorylation, activation, and nuclear translocation, thus preventing transcriptional activation of downstream signaling molecules to suppress colorectal cancer (CRC) proliferation and metastasis." | 3.96 | Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation. ( Chen, Z; Ding, Y; Li, K; Lian, W; Liao, Q; Lin, C; Lin, W; Tang, L; Wang, H; Wu, L; Xu, L; Zhao, L; Zhou, R, 2020) |
| "6 years, 54% men), a subgroup of 544 participants in the calcification side arm of the INSIGHT (International Nifedipine Study Intervention as Goal for Hypertension Therapy)." | 3.79 | Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults. ( Apter, S; Grossman, C; Grossman, E; Morag-Koren, N; Motro, M; Shemesh, J, 2013) |
| "The dihydropyridine derivatives increase [Ca(2+)](cyt) by potentiating the activity of CaSR in PASMC independently of their blocking (or activating) effect on Ca(2+) channels; therefore, it is possible that the use of dihydropyridine Ca(2+) channel blockers (eg, nifedipine) to treat IPAH patients with upregulated CaSR in PASMC may exacerbate pulmonary hypertension." | 3.79 | Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells. ( Guo, Q; Ko, EA; Makino, A; Pohl, NM; Smith, KA; Song, S; Wan, J; Yamamura, A; Yamamura, H; Yuan, JX; Zeifman, A; Zimnicka, AM, 2013) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "MCAs from srSHR and prestroke SHRSP exhibited pressure-dependent constriction and constricted in response to vasopressin or serotonin in the presence of nifedipine or the absence of [Ca2+]o." | 3.72 | Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction. ( Smeda, JS, 2003) |
| "A 31-year-old woman developed bilateral posterior ischemic optic neuropathy and infarctions of the cerebral arterial border zones and spinal cord after correction of malignant hypertension." | 1.35 | Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. ( An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE, 2008) |
| " In both age groups, chronic nifedipine administration reduced neurogenic contractions of isolated superior mesenteric artery, but did not significantly affect the dose-response curve to exogenous noradrenaline in 8-week-old rats." | 1.35 | Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. ( Török, J; Zemančíková, A, 2009) |
| "Treatment with nifedipine resulted in a significant inhibition of the progression of AAA such as aneurismal dilation at 14 and 28 days compared to the control (week 2: control, 2." | 1.35 | Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. ( Izawa, K; Kunugiza, Y; Morishita, R; Ogihara, T; Osako, MK; Tomita, N; Yamasaki, K, 2008) |
| "Does nifedipine treatment reduce the development and progression of diabetic vascular complications? If the answer is yes, is this beneficial effect of nifedipine superior than that of other DHPs with equihypotensive properties? Does nifedipine treatment decrease the incidence of melanoma and/or prolong the survival of patients with this devastating disorder? These prospective studies will provide further valuable information whether blockade by nifedipine of the AGE-RAGE signaling could be clinically relevant." | 1.33 | Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders. ( Nakamura, K; Takeuchi, M; Yamagishi, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 9 (26.47) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| de Heus, RAA | 1 |
| Olde Rikkert, MGM | 2 |
| Tully, PJ | 1 |
| Lawlor, BA | 1 |
| Claassen, JAHR | 1 |
| Dyer, AH | 1 |
| Murphy, C | 1 |
| Segurado, R | 2 |
| Lawlor, B | 2 |
| Kennelly, SP | 1 |
| Wu, L | 1 |
| Lin, W | 1 |
| Liao, Q | 1 |
| Wang, H | 1 |
| Lin, C | 1 |
| Tang, L | 1 |
| Lian, W | 1 |
| Chen, Z | 1 |
| Li, K | 1 |
| Xu, L | 2 |
| Zhou, R | 1 |
| Ding, Y | 1 |
| Zhao, L | 1 |
| Kennelly, S | 1 |
| Howard, R | 1 |
| Pasquier, F | 1 |
| Börjesson-Hanson, A | 1 |
| Tsolaki, M | 1 |
| Lucca, U | 1 |
| Molloy, DW | 1 |
| Coen, R | 1 |
| Riepe, MW | 1 |
| Kálmán, J | 1 |
| Kenny, RA | 1 |
| Cregg, F | 1 |
| O'Dwyer, S | 1 |
| Walsh, C | 1 |
| Adams, J | 1 |
| Banzi, R | 1 |
| Breuilh, L | 1 |
| Daly, L | 1 |
| Hendrix, S | 1 |
| Aisen, P | 1 |
| Gaynor, S | 1 |
| Sheikhi, A | 1 |
| Taekema, DG | 1 |
| Verhey, FR | 1 |
| Nemni, R | 1 |
| Nobili, F | 1 |
| Franceschi, M | 1 |
| Frisoni, G | 1 |
| Zanetti, O | 1 |
| Konsta, A | 1 |
| Anastasios, O | 1 |
| Nenopoulou, S | 1 |
| Tsolaki-Tagaraki, F | 1 |
| Pakaski, M | 1 |
| Dereeper, O | 1 |
| de la Sayette, V | 1 |
| Sénéchal, O | 1 |
| Lavenu, I | 1 |
| Devendeville, A | 1 |
| Calais, G | 1 |
| Crawford, F | 1 |
| Mullan, M | 1 |
| Shemesh, J | 2 |
| Motro, M | 2 |
| Grossman, C | 1 |
| Morag-Koren, N | 1 |
| Apter, S | 1 |
| Grossman, E | 1 |
| He, D | 1 |
| Lu, Y | 1 |
| Hu, H | 1 |
| Zhang, J | 1 |
| Qin, B | 1 |
| Wang, Y | 1 |
| Xing, S | 1 |
| Xi, Q | 1 |
| Wang, S | 1 |
| Lovell, MA | 1 |
| Abner, E | 1 |
| Kryscio, R | 1 |
| Fister, SX | 1 |
| Lynn, BC | 1 |
| Choi, JH | 1 |
| Choi, KD | 1 |
| Kim, JS | 1 |
| Kim, HJ | 1 |
| Lee, JE | 1 |
| An, SJ | 1 |
| Lüscher, TF | 1 |
| Pieper, M | 1 |
| Tendera, M | 1 |
| Vrolix, M | 1 |
| Rutsch, W | 1 |
| van den Branden, F | 1 |
| Gil, R | 1 |
| Bischoff, KO | 1 |
| Haude, M | 1 |
| Fischer, D | 1 |
| Meinertz, T | 1 |
| Münzel, T | 1 |
| Ganz, P | 1 |
| Ho, JE | 1 |
| Hsue, PY | 1 |
| Zemančíková, A | 1 |
| Török, J | 1 |
| Kayikçioğlu, M | 1 |
| Kültürsay, H | 1 |
| Tenney, JR | 1 |
| Schapiro, MB | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Nakazawa, M | 1 |
| Ohguro, H | 1 |
| Takeuchi, K | 1 |
| Miyagawa, Y | 1 |
| Ito, T | 1 |
| Metoki, T | 1 |
| Yamamura, A | 1 |
| Yamamura, H | 1 |
| Guo, Q | 1 |
| Zimnicka, AM | 1 |
| Wan, J | 1 |
| Ko, EA | 1 |
| Smith, KA | 1 |
| Pohl, NM | 1 |
| Song, S | 1 |
| Zeifman, A | 1 |
| Makino, A | 1 |
| Yuan, JX | 1 |
| Smeda, JS | 1 |
| Jerums, G | 1 |
| Allen, TJ | 1 |
| Campbell, DJ | 1 |
| Cooper, ME | 1 |
| Gilbert, RE | 1 |
| Hammond, JJ | 1 |
| O'Brien, RC | 1 |
| Raffaele, J | 1 |
| Tsalamandris, C | 1 |
| Inoue, S | 1 |
| Tomino, Y | 1 |
| Shinoda, E | 1 |
| Yui, Y | 1 |
| Kodama, K | 1 |
| Hirayama, A | 1 |
| Nonogi, H | 1 |
| Haze, K | 1 |
| Sumiyoshi, T | 1 |
| Hosoda, S | 1 |
| Kawai, C | 1 |
| Yamagishi, S | 1 |
| Nakamura, K | 1 |
| Takeuchi, M | 1 |
| Krasuski, RA | 1 |
| Griffin, BP | 1 |
| Hanyu, H | 1 |
| Hirao, K | 1 |
| Shimizu, S | 1 |
| Sato, T | 1 |
| Kiuchi, A | 1 |
| Iwamoto, T | 1 |
| Tomita, N | 1 |
| Yamasaki, K | 1 |
| Izawa, K | 1 |
| Kunugiza, Y | 1 |
| Osako, MK | 1 |
| Ogihara, T | 1 |
| Morishita, R | 1 |
| Aoki, T | 1 |
| Kataoka, H | 1 |
| Ishibashi, R | 1 |
| Nozaki, K | 1 |
| Hashimoto, N | 1 |
| Kametaka, S | 1 |
| Kasahara, T | 1 |
| Ueo, M | 1 |
| Takenaka, M | 1 |
| Saito, M | 1 |
| Sakamoto, K | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Jost, S | 1 |
| Deckers, J | 1 |
| Nikutta, P | 1 |
| Reiber, JH | 1 |
| Rafflenbeul, W | 1 |
| Wiese, B | 1 |
| Hecker, H | 1 |
| Lichtlen, P | 1 |
| Bannister, KM | 1 |
| Weaver, A | 1 |
| Clarkson, AR | 1 |
| Woodroffe, AJ | 1 |
| Acone, D | 1 |
| Cante, D | 1 |
| Cillo, F | 1 |
| Giordano, G | 1 |
| Giordano, C | 1 |
| Crepaldi, G | 1 |
| Carta, Q | 1 |
| Deferrari, G | 1 |
| Mangili, R | 1 |
| Navalesi, R | 1 |
| Santeusanio, F | 1 |
| Spalluto, A | 1 |
| Vanasia, A | 1 |
| Villa, GM | 1 |
| Nosadini, R | 1 |
| Monteiro de Freitas, AS | 1 |
| Coimbra, TM | 1 |
| Costa, RS | 1 |
| Baroni, EA | 1 |
| Ho, M | 1 |
| Belch, JJ | 1 |
| Simon, A | 1 |
| Gariépy, J | 1 |
| Moyse, D | 1 |
| Levenson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340] | Phase 3 | 511 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nifedipine and Disease Exacerbation
| Article | Year |
|---|---|
[Current approach to the treatment of pulmonary arterial hypertension and our experience in the Cardiology Department of Medicine Faculty of Ege University].
Topics: Antihypertensive Agents; Diltiazem; Disease Progression; Epoprostenol; Humans; Hypertension, Pulmona | 2009 |
Raynaud's phenomenon: state of the art 1998.
Topics: Biomarkers; Disease Progression; Humans; Nifedipine; Raynaud Disease; Vasodilator Agents | 1998 |
14 trials available for nifedipine and Disease Exacerbation
| Article | Year |
|---|---|
Blood Pressure Variability and Progression of Clinical Alzheimer Disease.
Topics: Aged; Alzheimer Disease; Antihypertensive Agents; Blood Pressure Determination; Cognition Disorders; | 2019 |
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili | 2020 |
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease | 2018 |
A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study.
Topics: Acetylcholine; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Calcium Channel Blockers | 2009 |
Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.
Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Disease Progression; Female; Follow-Up | 2011 |
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mel | 2004 |
Effects of calcium antagonists in hypertensive patients with renal dysfunction: a prospective, randomized, parallel trial comparing benidipine and nifedipine.
Topics: Calcium Channel Blockers; Dihydropyridines; Disease Progression; Female; Humans; Hypertension; Hyper | 2004 |
Nilvadipine prevents cognitive decline of patients with mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Cognition Disorders; D | 2007 |
Influence of the selection of angiographic projections on the results of coronary angiographic follow-up trials. International Nifedipine Trial on Antiatherosclerotic Therapy Investigators.
Topics: Analysis of Variance; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Meth | 1995 |
Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy.
Topics: Aldosterone; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Disease Progression | 1995 |
Blood pressure and progression of renal failure in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1996 |
Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab | 1998 |
Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.
Topics: Aged; Amiloride; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Coronary Artery Disease; Di | 2001 |
Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arter | 2001 |
18 other studies available for nifedipine and Disease Exacerbation
| Article | Year |
|---|---|
Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.
Topics: Calcium Channel Blockers; Colorectal Neoplasms; Disease Progression; Humans; NFATC Transcription Fac | 2020 |
Progression of coronary artery calcification is associated with long-term cardiovascular events in hypertensive adults.
Topics: Adult; Aged; Calcinosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Vessels; Disease | 2013 |
The Wnt11 Signaling Pathway in Potential Cellular EMT and Osteochondral Differentiation Progression in Nephrolithiasis Formation.
Topics: Animals; Biomarkers; Blotting, Western; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; | 2015 |
Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production.
Topics: Aged; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Antihypertensive Agents; Apolipoprotein | 2015 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; C | 2008 |
Structural and functional manifestations of human atherosclerosis: do they run in parallel?
Topics: Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Human | 2009 |
Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension.
Topics: Age Factors; Aging; Animals; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Block | 2009 |
Child neurology: alternating hemiplegia of childhood.
Topics: Age Factors; Calcium Channel Blockers; Child, Preschool; Diagnostic Imaging; Disease Progression; DN | 2010 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Cells, Cultured; Cyt | 2013 |
Stroke development in stroke-prone spontaneously hypertensive rats alters the ability of cerebrovascular muscle to utilize internal Ca2+ to elicit constriction.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models | 2003 |
Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Artery Disease; Disea | 2005 |
Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Topics: Calcium; Calcium Channel Blockers; Dihydropyridines; Disease Progression; Glycation End Products, Ad | 2005 |
Vasodilators in aortic regurgitation.
Topics: Antihypertensive Agents; Aortic Valve Insufficiency; Disease Progression; Enalapril; Humans; Hyperte | 2006 |
Inhibition of experimental abdominal aortic aneurysm progression by nifedipine.
Topics: Animals; Aortic Aneurysm, Abdominal; Blood Pressure; Blotting, Western; Calcium Channel Blockers; Ce | 2008 |
Nifedipine inhibits the progression of an experimentally induced cerebral aneurysm in rats with associated down-regulation of NF-kappa B transcriptional activity.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Dis | 2008 |
Effect of nifedipine on severe experimental cataract in diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Cataract; Diabetes Me | 2008 |
Urinary transforming growth factor-beta (TGF-beta) excretion and renal production of TGF-beta in rats with subtotal renal ablation: effect of enalapril and nifedipine.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Bloc | 1998 |